Regeneron’s Eylea: A Game Changer for Treatment of Macular Degeneration?

August 22, 2012

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) began selling Eylea late last year for treatment of wet macular degeneration.

Recently, the American Journal of Ophthalmology published a review of the medical literature and pertinent Internet postings combined with analysis of key studies with expert opinion regarding the use of Eylea (a/k/a aflibercept) for the treatment of wet AMD.

The authors concluded that Eylea promises to deliver excellent visual outcomes for wet age-related macular degeneration patients while undergoing fewer injections compared with Lucentis (a/k/a ranibizumab). With a wholesale cost of $1850 per dose, the cost per patient with Eylea treatment promises to be lower than with Lucentis.

Click here for access to the abstract.




Jump down to form below to submit your own comments

Comments are closed.